On September 11, 2025, PAVmed Inc.'s subsidiary, Lucid Diagnostics, sold 28,750,000 shares at $1.00 each, raising approximately $26.9 million for working capital. This offering included an underwriters' option fully exercised, as disclosed on the same date.